Vol 72, No 2 (2021)
Published online: 2021-04-30

open access

Page views 955
Article views/downloads 806
Get Citation

Connect on Social Media

Connect on Social Media

Adjuvant therapy in type 1 diabetes mellitus — choice or necessity in the COVID-19 pandemic?

Edyta Cichocka1
Pubmed: 33970478
Endokrynol Pol 2021;72(2):89-90.


Not available

Article available in PDF format

View PDF Download PDF file


  1. Cichocka E, Maj-Podsiadło A, Gumprecht J. Adjuvant therapy in type 1 diabetes mellitus. Endokrynol Pol. 2021; Ahead of Print.
  2. Al Khalifah RA, Alnhdi A, Alghar H, et al. The effect of adding metformin to insulin therapy for type 1 diabetes mellitus children: A systematic review and meta-analysis. Pediatr Diabetes. 2017; 18(7): 664–673.
  3. Libman IM, Miller KM, DiMeglio LA, et al. T1D Exchange Clinic Network Metformin RCT Study Group. Effect of Metformin Added to Insulin on Glycemic Control Among Overweight/Obese Adolescents With Type 1 Diabetes: A Randomized Clinical Trial. JAMA. 2015; 314(21): 2241–2250.
  4. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997; 18(6): 774–800.
  5. Escobar-Morreale HF, Roldán-Martín MB, Escobar-Morreale HF, et al. Type 1 Diabetes and Polycystic Ovary Syndrome: Systematic Review and Meta-analysis. Diabetes Care. 2016; 39(4): 639–648.
  6. Milewicz A, Kudła M, Spaczyński RZ, et al. The polycystic ovary syndrome: a position statement from the Polish Society of Endocrinology, the Polish Society of Gynaecologists and Obstetricians, and the Polish Society of Gynaecological Endocrinology. Endokrynol Pol. 2018; 69(4).
  7. Casu A, Bilal A, Pratley RE, et al. Advancing Care for Type 1 Diabetes, Obesity Network (ACT1ON). Pharmacological therapies to address obesity in type 1 diabetes. Curr Opin Endocrinol Diabetes Obes. 2020; 27(4): 194–206.
  8. Maj-Podsiadło A, Cichocka E, Gumprecht J, et al. SGLT-2 inhibitors as adjunctive to insulin therapy in type 1 diabetes. Clin Diab. 2020; 9(3): 189–192.
  9. Huang Y, Jiang Z, Wei Y, et al. Short- and medium-term efficacy of sodium glucose cotransporter 2 (SGLT-2) inhibitors for the treatment of type 1 diabetes: systematic review and meta-analysis. Endokrynol Pol. 2020; 71(4): 325–333.
  10. Yamada T, Shojima N, Noma H, et al. Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin for type 1 diabetes mellitus: Systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2018; 20(7): 1755–1761.
  11. Danne T, Cariou B, Buse JB, et al. Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program. Diabetes Care. 2019; 42(5): 919–930.
  12. Danne T, Garg S, Peters AL, et al. International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors. Diabetes Care. 2019; 42(6): 1147–1154.
  13. Dejgaard TF, Frandsen CS, Hansen TS, et al. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2016; 4(3): 221–232.
  14. Mathieu C, Zinman B, Hemmingsson JU, et al. ADJUNCT ONE Investigators. Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial. Diabetes Care. 2016; 39(10): 1702–1710.